Global Bispecific Antibody Market, Drug Sales and Clinical Pipeline Insight 2025

” Global Bispecific Antibody Market, Drug Sales  and Clinical Pipeline Insight 2025″ Report Highlights:

• Applications of Bispecific Antibodies

• Global Bispecific Antibody Market Overview: Drug and Market Sales

• Global Bispecific Antibody Market Opportunity: US$  8 Billion by 2025

• US and Japan Market Share Opportunity: andgt;40% by 2025

• Bispecific Antibody Clinical Pipeline: 224 Drugs

• Commercially Available Bispecific Antibody: 2 (HEMLIBRA and  Blincyto)

Download Report Sample:  https://www.kuickresearch.com/report-global-bispecific-antibody-market,-drug-sales–and-clinical-pipeline-insight-2025.php

The research and development of bispecific antibodies has emerged as a new unexplored growth frontier for pharmaceutical industry as per recent research study “Global Bispecific Antibody Market, Drug Sales  and Clinical Pipeline Insight 2025″ published by Kuick Research. As per report findings, the market opportunity of bispecific antibodies is estimated to surpass US$ 8 Billion by 2025 driven by application of existing commercially available bispecific antibodies to other multiple indications and increasing regulatory approvals from developing and developed markets. Currently, there are 2 bispecific antibodies (HEMLIBRA and  Blincyto) commercially available in the market with combined sales of less than US$ 1 Billion in 2018.

The market for bispecific antibodies is quiet bright as they are the new emerging trends in the market. BsAbs due their specificity are gaining a lot of interest from multiple stake holders from the pharmaceutical industry. Now with the improved technology, monoclonal antibody therapy witnessed a drastic transition and is becoming more acceptable due to its site specific approach. They have become a critical component of clinical treatment procedure for a variety of indications.

Therapeutic antibodies in various segments have made the transition from human conception to clinical reality over the past two decades and reached from labs to bedside of the patients. Now, many of mAbs are being tested as adjuvant or first-line therapies to determine their efficacy in improving survival. The market is no doubt flourishing and is sure to increase many folds as with due acceptance of clinicians and patients due to their targeted effect.

Currently, there are more than 200 bispecific antibodies in the clinical trials and this number is further expected to increase in coming years driven by research and development and the favorable commercial success to 2 bispecific antibodies available in the market. Most of bispecific antibodies are being developed for the treatment of multiple cancers followed by infectious disease, CNS disorders, inflammatory and autoimmune disorders. The future for the research and development of bispecific antibodies remains highly progressive and profitable option driven by the fact that increasing number of big and small pharmaceutical companies are allocating their resources and are collaborating with other stake holders of the industry.

 

1. History of Monoclonal Antibodies

2. Overview of Bispecific Monoclonal Antibody

3. Mechanism Of Action Of Bispecific Antibody

  3.1 Trifunctional Antibody: Catumaxomab (Removabandreg;)

  3.2 Blinatumomab

4. The Design and Engineering of IgG like Bispecific Antibodies

  4.1 Quadroma (Hybrid Hydromas) Approach

  4.2 “Knobs Into Holes” Approach

  4.3 CrossMab Approach

  4.4 Dual-Variable-Domain Immunoglobulin Approach

5. The Design and Engineering of Small Bispecific Antibodies

  5.1 Bispecific Diabodies

  5.2 Bispecific T-Cell Engager Antibodies (BiTEs)

6. Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies

7. Applications of Bispecific Antibodies

  7.1 BsMAb for Diagnosis of Infectious Diseases

    7.1.1 Diagnosis of Bacterial Infections

    7.1.2 Diagnosis of Viral Infections

  7.2 BsMAb for Cancer Diagnostic

  7.3 BsAbs Blocking Signaling Pathways

  7.4 BsAbs Targeting Tumor Angiogenesis

  7.5 Specific Delivery of Effector Compounds to Targets

  7.6 Bispecific Antibodies and Gene Therapy

8. Global Bispecific Antibody Market Overview

  8.1 Current Market Scenario

    8.1.1 Catumaxomab (Removab)

    8.1.2 Blinatumomab

    8.1.3 Duligotumab

    8.1.4 SAR 156597

  8.2 Global Bispecific Antibodies Clinical Pipeline Overview

9. Global Bispecific Antibody Market Dynamics

  9.1 Favorable Market Parameters

    9.1.1 Target Patient Base

    9.1.2 Severity Of The Disease

    9.1.3 Unavailability Of Completely Curing Drugs

    9.1.4 Side Effects of the Existing Drugs

    9.1.5 Specificity of Monoclonal Antibodies in Targeting Cancer Cells

  9.2 Commercialization Challenges

    9.2.1 Stringent Regulatory Guidelines

    9.2.2 Long Duration of Research and Development

    9.2.3 Clinical Trial Timeline

    9.2.4 High Cost for Research and Development

10. Global Bispecific Antibody Market Future Prospects

11. Global Bispecific Antibodies Clinical Pipeline by Company, Indication and Phase

  11.1 Research

  11.2 Preclinical

  11.3 Phase-I

  11.4 Phase-I/II

  11.5 Phase-II

  11.6 Phase-III

12. Marketed Global Bispecific Antibodies Clinical Insight by Company and Indication

  12.1 Emicizumab (HEMLIBRA)

  12.2 Blinatumomab (Blincyto)

13. No Development Reported and Discontinued Global Bispecific Antibodies Clinical Pipeline by Company, Indication and Phase

  13.1 No Development Reported

  13.2 Discontinued

  13.3 Market Withdrawal

14. Competitive Landscape

  14.1 Ablynx

  14.2 Adimab

  14.3 Affimed Therapeutics

  14.4 Amgen

  14.5 AstraZeneca (MedImmune)

  14.6 Chugai Pharmaceutical

  14.7 Eli Lilly

  14.8 EMD Serono

  14.9 Emergent BioSolutions

  14.10 Genentech

  14.11 Genmab

  14.12 Immunomedics

  14.13 Jounce Therapeutics

  14.14 MacroGenics

  14.15 Merus

  14.16 Neovii Biotech

  14.17 NovImmune SA

  14.18 OncoMed Pharmaceuticals

  14.19 Pieris

  14.20 Regeneron Pharmaceuticals

  14.21 Roche

  14.22 Sanofi

 

Figure 3-1: Mechanism of Action of Bispecific Monoclonal Antibody

Figure 3-2: Mechanism of Action of Catumaxomab

Figure 3-3: Mechanism of Action of Blinatumomab

Figure 4-1: Types of Approaches to Form IgG like Bispecific Antibodies

Figure 4-2: Method of Formation of Hybrid Hybridoma

Figure 4-3: Limitations of Hybrid Hybridoma

Figure 4-4: Steps involved in “Knobs into Holes” Approach

Figure 4-5: Three different CrossMabs are Obtained by Three Different Modifications

Figure 4-6: Method for formation of Dual-Variable-Domain Immunoglobulin

Figure 4-7: Advantages of Dual Variable Domain Immunoglobulin approach

Figure 5-1: Types of Bispecific Antibodies

Figure 6-1: Advantages of Bispecific Antibodies

Figure 7-1: Applications of Bispecific Antibodies

Figure 8-1: BLINCYTO – US v/s Rest of World Sales Share (%), 2017

Figure 8-2: BLINCYTO – US v/s Rest of World Sales Share (%), Q3’2018

Figure 8-3: BLINCYTO – US v/s Rest of World Sales (US$ Million), Q3’2018

Figure 8-4: BLINCYTO – Global Sales (US$ Million), Q1’2018 to Q3’2018

Figure 8-5: BLINCYTO – US and Rest of World Sales (US$ Million), Q1’2018 to Q3’2018

Figure 8-6: Global – Bispecific Antibodies Clinical Pipeline by Phase (%), 2019 till 2025

Figure 8-7: Global – Bispecific Antibodies Clinical Pipeline by Phase (Numbers), 2019 till 2025

Figure 8-8: Global – Inactive Bispecific Antibodies in Clinical Pipeline by Phase (%),2019 till 2025

Figure 8-9: Global – Inactive Bispecific Antibodies in Clinical Pipeline by Phase (Numbers), 2019 till 2025

Figure 9-1:  Favorable Market Parameters Global Bispecific Antibody Market

Figure 9-2: Commercialization Challenges for Bispecific Antibody

Figure 10-1: Japan – HEMLIBRA Market Opportunity For Treatment of Hemophilia A  ( US$ Million), 2019 – 2025

Figure 10-2: Global  – HEMLIBRA Market Opportunity For Treatment of Hemophilia A- Inhibitors ( US$ Million), 2019 – 2025

Figure 10-3: USA  – HEMLIBRA Market Opportunity For Treatment of Hemophilia A- Inhibitors ( US$ Million), 2019 – 2025

Figure 10-4: Global  – HEMLIBRA Market Opportunity For Treatment of Hemophilia A – Non Inhibitors ( US$ Million), 2019 – 2025

Figure 10-5: USA  – HEMLIBRA Market Opportunity For Treatment of Hemophilia A – Non Inhibitors ( US$ Million), 2019 – 2025

Figure 10-6: Global  – Bispecific Antibody Market Opportunity ( US$ Billion), 2019 – 2025

Figure 14-1: Ablynx – Clinical Pipeline

Figure 14-2: Affimed Therapeutics – Clinical Pipeline

Figure 14-3: Amgen – Clinical Pipeline

Figure 14-4: EMD Serono – Clinical Pipeline

Figure 14-5: Emergent Bioscience – Clinical Pipeline

Figure 14-6: Genmab – Clinical Pipeline

Figure 14-7: Jounce Therapeutics – Clinical Pipeline

Figure 14-8: MacroGenics – Clinical Pipeline

Figure 14-9: Merus – Clinical Pipeline

Figure 14-10: Novimmune – Clinical Pipeline

Figure 14-11: OncoMed – Clinical Pipeline

Figure 14-12: Pieris Pharmaceuticals – Clinical Pipeline

Figure 14-13: Roche – Clinical Pipeline

 

 

 

Table 4-1: List of Bispecific Antibodies Formed by Hybrid Hybridoma Method

Table 5-1: List of Bispecific Antibodies Formed by DART

Table 5-2: List of Bispecific Antibodies Formed by BiTE Method

Table 5-3: List of Other BiTEs

Table 7-1: Bispecific Antibodies Targeting Cancer